[Announcement] Notice on the posting of the column of Vice President Nam Young-il of BioPassport

Hello, This is the Biopassport Team.
We announce the column of Vice President Nam Young-il of BioPassport being published in the media.

The column title is “Actually Endemic, will non-face-to-face treatment survive?”, which deals with the future prospects of the survival of the non-face-to-face treatment industry itself, following the recent decision by the World Health Organization to lift the state of emergency for COVID-19.

It explains the changes in the non-face-to-face treatment bill, what kind of non-face-to-face treatment pilot projects the government has conducted for companies, and what questions the public has posted about the effectiveness of non-face-to-face treatment. In addition, Vice President Nam Young-il explained about the advantages of non-face-to-face treatment in real life in modern society.

Since it is a column related to the direction of the BioPassport business, there are many things that investors can refer to, so we will guide you through the column posted.
Please refer to the link below for details.

[Column] Actually Endemic, will non-face-to-face treatment survive?https://newsborn.co.kr/news/news_view.php?idx_no=15609

Thank you.
BioPassport Team